UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 2158-7
Program Prior Authorization/Medical Necessity
Medication Jivi® (antihemophilic factor [recombinant], PEGylated-aucl)
P&T Approval Date 1/2019, 2/2020, 9/2020, 9/2021, 9/2022, 9/2023, 9/2024
Effective Date 12/1/2024
1. Background
Jivi (antihemophilic factor [recombinant], PEGylated-aucl) is a recombinant DNA-derived,
Factor VIII concentrate indicated for use in previously treated adults and adolescents (12 years
of age and older) with hemophilia A (congenital Factor VIII deficiency) for:1
On-demand treatment and control of bleeding episodes
o
Routine prophylaxis to reduce the frequency of bleeding episodes
o
Perioperative management of bleeding
o
Jivi is not indicated for use in children < 12 years of age due to a greater risk for
hypersensitivity reactions. Jivi is not indicated for use in previously untreated patients (PUPs).
Jivi is not indicated for the treatment of von Willebrand disease.
2. Coverage Criteriaa:
A. Initial Authorization:
1. Jivi will be approved based on all of the following criteria:
a. Diagnosis of hemophilia A
-AND-
b. Patient is 12 years of age or older
-AND-
c. Patient has previously received Factor VIII replacement therapy
-AND-
d. Patient is not a suitable candidate for treatment with shorter acting half-life Factor VIII
(recombinant) products [Advate, Kogenate FS, Kovaltry, Novoeight, Nuwiq, or
Recombinate] as attested by the prescriber
-AND-
e. Patient is not to receive routine infusions more frequently than 2 times per week
© 2024 UnitedHealthcare Services, Inc.
1
Authorization of therapy will be issued for 12 months.
B. Reauthorization
1. Jivi will be approved based on both of the following criteria:
a. Documentation of positive clinical response to Jivi therapy.
-AND-
b. Patient is not to receive routine infusions more frequently than 2 times per week
Authorization of therapy will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Programs:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
4. References:
1. Jivi® [package insert]. Whippany, BJ: Bayer HealthCare, LLC., August 2018.
2. MASAC Recommendations Concerning Products Licensed for the Treatment of
Hemophilia and Selected Disorders of the Coagulation System. MASAC Document #284,
April 11, 2024.
Program Prior Authorization/Medical Necessity - Jivi
Change Control
1/2019 New program.
2/2020 Annual review with no changes to clinical coverage criteria.
9/2020 Updated preferred standard half-life recombinant products. Updated
reference.
9/2021 Annual review with no changes to clinical coverage criteria.
9/2022 Annual review with no changes to clinical coverage criteria. Updated
background per prescribing information and updated references.
9/2023 Annual review. Modified physician attestation to prescriber attestation.
Updated references.
9/2024 Annual review with no changes to clinical coverage criteria. Updated
references.
© 2024 UnitedHealthcare Services, Inc.
2